Standard Life Investments LTD cut its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 111,106 shares of the company’s stock after selling 369 shares during the period. Standard Life Investments LTD’s holdings in Thermo Fisher Scientific were worth $16,417,000 as of its most recent SEC filing.
Several other institutional investors have also bought and sold shares of the company. Bank of Montreal Can acquired a new position in Thermo Fisher Scientific during the second quarter worth about $32,053,000. Carmignac Gestion increased its position in Thermo Fisher Scientific by 23.3% in the second quarter. Carmignac Gestion now owns 4,046,550 shares of the company’s stock worth $597,918,000 after buying an additional 763,421 shares during the last quarter. Bellevue Group AG acquired a new position in Thermo Fisher Scientific during the first quarter worth about $2,832,000. Artemis Investment Management LLP increased its position in Thermo Fisher Scientific by 54.6% in the second quarter. Artemis Investment Management LLP now owns 172,789 shares of the company’s stock worth $25,530,000 after buying an additional 61,046 shares during the last quarter. Finally, Puplava Financial Services Inc. increased its position in Thermo Fisher Scientific by 0.8% in the second quarter. Puplava Financial Services Inc. now owns 8,819 shares of the company’s stock worth $1,303,000 after buying an additional 71 shares during the last quarter. 87.38% of the stock is currently owned by institutional investors.
Shares of Thermo Fisher Scientific Inc. (NYSE:TMO) traded up 0.10% during midday trading on Thursday, reaching $158.44. 998,070 shares of the company traded hands. Thermo Fisher Scientific Inc. has a 1-year low of $119.75 and a 1-year high of $160.68. The stock has a 50 day moving average price of $153.07 and a 200 day moving average price of $150.36. The firm has a market capitalization of $62.47 billion, a PE ratio of 31.69 and a beta of 0.97.
Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Thursday, July 28th. The company reported $2.03 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.01 by $0.02. Thermo Fisher Scientific had a net margin of 11.35% and a return on equity of 14.70%. The company had revenue of $4.54 billion for the quarter, compared to the consensus estimate of $4.50 billion. During the same quarter in the prior year, the company earned $1.84 EPS. Thermo Fisher Scientific’s quarterly revenue was up 6.2% on a year-over-year basis. Analysts expect that Thermo Fisher Scientific Inc. will post $8.17 earnings per share for the current fiscal year.
A number of equities analysts recently issued reports on TMO shares. Cleveland Research downgraded shares of Thermo Fisher Scientific from a “buy” rating to a “neutral” rating in a report on Friday, September 9th. JPMorgan Chase & Co. started coverage on shares of Thermo Fisher Scientific in a report on Thursday, September 22nd. They issued an “overweight” rating and a $180.00 price objective on the stock. Zacks Investment Research raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $175.00 price objective on the stock in a report on Wednesday, July 20th. Citigroup Inc. raised their price objective on shares of Thermo Fisher Scientific from $160.00 to $182.00 and gave the stock a “buy” rating in a report on Friday, July 29th. Finally, Mizuho set a $175.00 price target on shares of Thermo Fisher Scientific and gave the company a “buy” rating in a report on Thursday, July 28th. Three research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $160.79.
In other Thermo Fisher Scientific news, SVP Thomas W. Loewald sold 8,025 shares of the company’s stock in a transaction that occurred on Wednesday, July 13th. The stock was sold at an average price of $155.00, for a total value of $1,243,875.00. Following the sale, the senior vice president now owns 52,194 shares in the company, valued at approximately $8,090,070. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Marc N. Casper sold 30,000 shares of the company’s stock in a transaction that occurred on Thursday, September 1st. The stock was sold at an average price of $151.17, for a total value of $4,535,100.00. Following the completion of the sale, the chief executive officer now owns 308,647 shares in the company, valued at approximately $46,658,166.99. The disclosure for this sale can be found here. 0.52% of the stock is currently owned by corporate insiders.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company is a provider of analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. The company operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).
Receive News & Ratings for Thermo Fisher Scientific Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc. and related companies with MarketBeat.com's FREE daily email newsletter.